Can antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis cause secondary focal segmental glomerulosclerosis (FSGS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ANCA Vasculitis Does Not Cause Primary FSGS, But Can Present With Focal Global Glomerulosclerosis

ANCA-associated vasculitis does not cause focal segmental glomerulosclerosis (FSGS) as a primary disease pattern. The characteristic kidney lesion in ANCA vasculitis is pauci-immune necrotizing and crescentic glomerulonephritis, not FSGS 1, 2, 3.

Understanding the Distinction

Primary Pattern of ANCA Vasculitis

  • The hallmark renal pathology is pauci-immune focal and segmental necrotizing and crescentic glomerulonephritis (NCGN), not FSGS 2, 3
  • This presents with glomerular necrosis, cellular crescents, and minimal immune complex deposition on immunofluorescence 3, 4
  • The pattern is characterized by active inflammatory injury rather than the podocyte injury and scarring seen in primary FSGS 1

Focal Global Glomerulosclerosis vs. FSGS

The confusion may arise from terminology, but these are distinct entities:

  • Focal global glomerulosclerosis refers to completely scarred glomeruli and is listed as an "additional feature" in ANCA GN, representing chronic damage from prior inflammation 1
  • The Mayo Clinic/Renal Pathology Society consensus shows ANCA GN can have focal global glomerulosclerosis (10-40% of glomeruli) as a secondary chronic finding 1
  • This is fundamentally different from primary FSGS, which shows segmental sclerosis within individual glomeruli with podocyte foot process effacement 1

Clinical Implications

What You Actually See on Biopsy

When evaluating a kidney biopsy in ANCA vasculitis:

  • Primary diagnosis: ANCA GN (MPO-ANCA or PR3-ANCA) 1
  • Pattern of injury: Necrotizing and crescentic GN 1
  • Additional features: May include focal global glomerulosclerosis representing chronic scarring from previous inflammation 1
  • The histopathologic classification focuses on the percentage of normal glomeruli, crescentic glomeruli, and globally sclerotic glomeruli 1

Rare Case Report Exception

  • One isolated case report from 1996 described ANCA positivity in a patient with FSGS on biopsy 5
  • However, this represents either coincidental ANCA positivity or possible secondary vasculitis complicating immune complex disease, not ANCA vasculitis causing FSGS 5
  • This single low-quality report does not establish a causal relationship and contradicts the established pathologic classification 1

Key Pitfall to Avoid

Do not confuse "focal global glomerulosclerosis" (completely scarred glomeruli) with "focal segmental glomerulosclerosis" (FSGS - segmental scarring within glomeruli). These are entirely different pathologic entities with different clinical implications 1. The former is a chronic sequela of many glomerular diseases including ANCA vasculitis, while the latter is a specific podocytopathy.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Renal Vasculitis Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

ANCA-associated vasculitis with renal involvement.

Journal of nephrology, 2018

Research

Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003

Research

[Anti-neutrophil cytoplasmic antibodies (ANCA) in the glomerulonephritis].

Polskie Archiwum Medycyny Wewnetrznej, 1996

Related Questions

What is the management of Anti-Neutrophil Cytoplasmic Antibody (ANCA) nephritis?
What is the significance of atypical c-ANCA (cytoplasmic anti-neutrophil cytoplasmic antibodies) in a patient with chronic kidney disease (CKD)?
What is the management approach for a patient with a bladder adenoma and a history of ANCA (Antineutrophil Cytoplasmic Antibody)-associated vasculitis?
What is the initial treatment for a patient with c-ANCA (cytoplasmic anti-neutrophil cytoplasmic antibodies) vasculitis and impaired renal function (creatinine level of 2.4)?
In a 41-year-old man with a two‑month history of sinus pain and congestion with epistaxis, a productive cough of brown sputum, a purpuric rash on the lower legs, 20‑lb weight loss, myalgias, arthralgias, intermittent fever up to 102°F, an erythrocyte sedimentation rate of 60 mm/hr, positive cytoplasmic antineutrophil cytoplasmic antibody (c‑ANCA), positive rheumatoid factor, negative antinuclear antibody (ANA), and renal involvement evidenced by proteinuria, hematuria and red‑cell casts, what is the most likely diagnosis?
What are the risk factors for seizures during withdrawal from alprazolam (Xanax)?
In a patient who has had an acute myocardial infarction, when should beta‑blockers be started, what are the contraindications, preferred agents and dosing, and how long should therapy be continued?
When does pneumoperitoneum resolve after laparoscopic (including diagnostic or exploratory) surgery?
What is the appropriate starting dose and titration schedule for Ozempic (semaglutide) in an adult with type 2 diabetes, and what are its contraindications and major adverse effects?
After an exploratory laparotomy, how long should postoperative pneumoperitoneum resolve, and when should persistent free intraperitoneal air be investigated and managed?
What is the appropriate emergency management for a central corneal infiltrate identified on a dark‑room slit‑lamp examination?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.